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AADC deficiency is a rare genetic disease caused by mutations in the gene of aromatic amino acid 
decarboxylase, the pyridoxal 5'-phosphate dependent enzyme responsible for the synthesis of 
dopamine and serotonin. Here, following a biochemical approach together with an in silico 
bioinformatic analysis, we present a structural and functional characterization of 13 new variants of 
AADC. The amino acid substitutions are spread over the entire protein from the N-terminal 
(V60A), to its loop1 (H70Y and F77L), to the large domain (G96R) and its various motifs, i.e. 
loop2 (A110E), or a core -barrel either on the surface (P210L, F251S and E283A) or in a more 
hydrophobic milieu (L222P, F237S and W267R) or loop3 (L353P), and to the C-terminal domain 
(R453C). Results show that the -barrel variants exhibit a low solubility and those belonging to the 
surface tend to aggregate in their apo form, leading to the identification of a new enzymatic 
phenotype for AADC deficiency. Moreover, five variants of residues belonging to the large 
interface of AADC (V60A, G96R, A110E, L353P and R453C) are characterized by a decreased 
catalytic efficiency. The remaining ones (H70Y and F77L) present features typical of apo-to-holo 
impaired transition. Thus, defects in catalysis or in the acquirement of the correct holo structure are 
due not only to specific local domain effects but also to long-range effects at either the protein 
surface or the subunit interface. Altogether, the new characterized enzymatic phenotypes represent 
a further step in the elucidation of the molecular basis for the disease. 
 
 
Keywords: pyridoxal 5'-phosphate enzymes, aromatic amino acid decarboxylase deficiency, 
AADC deficiency variants, structure and function relationship, protein chemistry, enzymology 
 






Aromatic amino acid decarboxylase (AADC) deficiency is a rare autosomic disease first reported 
by Hyland et al. [1, 2] nearly 30 years ago. It is caused by mutations (mainly missense but also 
frameshift and splicing alterations) present in homozygosis or compound heterozygosis in the gene 
encoding for AADC, the pyridoxal 5'-phosphate (PLP) enzyme responsible for the synthesis of 
dopamine and serotonin following decarboxylation of L-Dopa and 5-hydroxytryptophan [3, 4]. The 
disease is mainly diagnosed in infancy and exhibits many different symptoms reflecting the lack or 
low levels of catechol and indole biogenic amines. Patients experience several altered physiological 
functions such as hypotonia, hypokinesia, oculogyric crises, development and behavioural 
problems, autonomic dysfunctions such as nasal congestion, modified circadian rhythm, pain and 
temperature instability [5-10]. The present pharmacological treatment foresees a combination of 
pyridoxine, the precursor of PLP to keep AADC saturated with its coenzyme, monoamine oxidase 
inhibitors, to avoid dopamine and serotonin further depletion, and dopamine agonists, to mimic the 
effect of dopamine. Unfortunately, in many cases, the response is generally poor and this infantile 
form of Parkinsonism is particularly threatening and, in the most severe forms, leads to death in the 
first decade of life. 
Up to now, nearly 120 patients have been identified worldwide [9], but the number is continuously 
growing since knowledge about this defect is increasing among child neurologists. Moreover, the 
extent of affected people might be even higher considering i) newly reported case of a heterozygous 
patient that possesses one allele with a mild mutation, while the other allele has no mutations [11], 
ii) another heterozygous case with typical AADC deficiency symptoms (case II-2 in [12]) and iii) a 
milder case of AADC deficiency reported by [13]. These unsuspected patients expand the spectrum 
of AADC deficiency with recent estimates [14, 15] predicting that the number of affected people is 
higher than reported and many patients remain not diagnosed or misdiagnosed [15]. 
In order to counteract AADC deficiency, some strategies have currently been undertaken. Firstly, a 
gene therapy approach has been carried out in Taiwan by Dr. Hwu and co-workers [16-19] and in 
Japan [20] with some patients, leading to some benefits but still not decisive improvements. 
Secondly, mouse models with different genetic defects have been generated to simulate AADC 
deficiency and understand the human disease [21-24], but much has still to be done. 
A biochemical research of genotype to phenotype correlation has been carried out in order to 
elucidate the molecular basis of an altered phenotype by characterizing the related enzymatic 
variant. Previously, the structural/functional correlation of the effects of mutations for 16 AADC 
variants were studied [25]. This approach deepened the understanding of the role played by 
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individual amino acids on enzyme structure and function, suggesting more effective therapeutic 
interventions.  
After five years the number of identified mutations has rapidly increased. The total number of the 
identified AADC mutations leading to the disease, including missense mutations determining 
homozygosis or compound heterozygosis, insertions, deletions, introns and non-coding regions 
modifications, has been recently updated [15]. In particular, 13 new mutations have been identified 
in homozygosis or hemizygosis and their protein variants are listed in Table 1. Notably, the variants 
of His-70 and Ala-110 have been re-characterized since they were incorrectly reported (see Table 
1). 
On the basis of the structure of AADC, solved both in the pig holo (~ 90% sequence identity with 
the human enzyme) [26] and in the human apo form [27], the new sites of mutation are spread 
overall the entire protein and not only in the central part of each monomer as previously claimed 
[25] (Fig. 1).  
Here, by a combination of bioinformatic and physico-chemical techniques, we present a structural 
and functional characterization of the new homozygous and hemizygous variants of AADC. The 
data obtained pertain to residues that belong to: i) loop1 (aa 66-84) of the N-terminal region (H70Y 
and F77L), ii) the interface between monomers (V60A, G96R, A110E, L353P and R453C) and iii) 
different regions of the large domain (P210L, L222P, F237S, F251S, W267R and E283A). The 




2. Materials and Methods 
 
2.1 Materials 
PLP, L-Dopa, dopa methylester (DME), hydroxylamine hydrochloride, isopropyl--d-
thiogalactopyranoside (IPTG), trinitrobenzenesulfonic acid (TNB), phenylmethylsulfonyl 
fluoride (PMSF), protease inhibitor cocktail (P8849), were purchased from Sigma. Anti AADC 
monoclonal antibody (8E8) and mouse IgG kappa binding protein (m-IgGk BP) conjugated with 
HRP were purchased from Santa Cruz Biotechnology. 
 
2.2 Site-directed mutagenesis 
AADC variants were obtained by mutating the template DNA on the pDDChis vector as previously 
described [25]. Each mutagenesis reaction has been performed using the Quick-Change II kit 
(Agilent technologies) using the appropriate oligonucleotides (summarized in Table S1) and their 
complements. All mutations were confirmed by DNA sequence analysis of the whole ORF.  
 
2.3 Expression and Purification of AADC variants 
E. coli BL21 (DE3) cells were transformed by heat shock at 42°C with the desired construct and 
grown in 4.5 L of Luria–Bertani (LB) broth in presence of ampicillin (100 mg/ml). The cultures 
were grown at 37°C to an OD600nm of 0.4-0.6, and expression was induced with 0.1 mM IPTG for 
15 h at 30°C. Cells were harvested and resuspended in 20 mM sodium phosphate buffer pH 7.4, 
containing 0.5 M NaCl, 20 mM imidazole, 50 μM PLP, 0.5 mM PMSF and protease inhibitor 
cocktail. Lysozyme was then added to a concentration of 0.2 mg/ml and the culture was incubated 
for 20 min at room temperature. After a freeze-thaw, leupeptin and pepstatin (both at 1μg/ml 
concentration) were added and the suspension was centrifuged at 16,000 g for 30 min. The crude 
cellular lysate was loaded on a HisPrep FF 16/10 column (GE Healthcare) equilibrated with 20 mM 
sodium phosphate buffer pH 7.4, containing 0.5 M NaCl and 20 mM imidazole. AADC was eluted 
with a linear gradient (0-100% in 200 ml) of the same buffer containing 500 mM imidazole. After 
addition of 50 μM PLP, the protein solution was concentrated and imidazole and unbound 
coenzyme were removed by extensive washing with 100 mM potassium phosphate buffer pH 7.4, 
using Amicon Ultra 15 concentrators (Millipore). The enzymes concentration was determined using 
an εM of 1.42 x 105 M−1cm−1 at 280 nm. PLP content was determined by releasing the coenzyme in 
0.1 M NaOH using εM of 6600 M−1cm−1 at 388 nm [28]. 
 
2.4 Size-Exclusion liquid chromatography  
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Size-exclusion liquid chromatography was applied as further purification step. Samples were loaded 
on a Superdex 200 (10/300) (GE Healthcare) column equilibrated with 100 mM potassium 
phosphate buffer pH 7.4, on an Akta FPLC system (GE Healthcare). The run was performed using 
the same buffer at a flow rate of 0.3 ml/min with detection at 280 nm.  
 
2.5 Determination of solubility level of the AADC variants 
E. coli has been used as a model for the expression study of the pathogenic AADC variants. 
Chemical competent bacteria were transformed with the proper mutagenized plasmid as described 
in the expression and purification section. Cultures were grown even in the absence or in the 
presence of 50 μM exogenous PLP and 1 mL of each culture was processed following the same 
procedure described above. After lysis, samples were treated with DNase (10 U) at room 
temperature for 30 min. The whole cell extract was separated by centrifugation at 13200 rpm, 10 
min, 4°C. Total protein content in the crude cellular lysate was quantified and 15 g of total protein 
was run on a 12% (w/w) SDS-PAGE gel. The same amount of a sample consisting of the membrane 
insoluble pellet of wild-type (WT), P210L, L222P, F237S, W267R and E283A variants was 
analyzed. Proteins from the gel were transferred on a nitrocellulose membrane by a Mini Trans-Blot 
cell (Bio-Rad). Membrane was blocked with a 5% (w/w) milk solution at 37°C for 1 hour and, after 
the washing steps, it was incubated with a 1:200 (v/v) diluted anti-AADC monoclonal antibody 
solution over night at 4°C. Membrane was then washed and then incubated with a 1:4000 (v/v) anti-
mouse secondary antibody solution for 1 hour at 25°C. Blotted proteins were detected and 
quantified with ECL (Millipore), using the ChemiDoc XRS Imaging System (Bio-Rad, Hercules, 
CA). Quantification of the band was obtained with ImageJ software (Fiji).  
 
2.6 Apoenzyme preparation and coenzyme binding affinity measurements 
Apoenzyme was obtained by incubating 5 µ holoenzyme with 10 mM hydroxylamine in 0.5 M 
potassium phosphate buffer pH 6.8 at 25°C for 3 hours. The solution was then loaded on a 
Desalting 26/10 column (GE Healthcare) pre-equilibrated with 0.5 M potassium phosphate buffer 
pH 6.8 and eluted at 1 mL/min. The eluted enzyme was then concentrated on an Amicon Ultra 15 
concentrators (Millipore) and washed with 100 mM potassium phosphate buffer pH 7.4. 
The equilibrium apparent dissociation constant for PLP, KD(PLP), was determined by measuring the 
quenching of the intrinsic fluorescence of 0.1 µM AADC apoenzyme incubated in the presence of 
PLP at concentrations ranging from 0.005 to 20 μM for 3h at 25°C (in the dark) in 100 mM 
potassium phosphate buffer pH 7.4.  




where [E]t and [PLP]t represent the total concentrations of the enzyme and PLP, respectively, Y 
refers to the intrinsic quenching changes at a PLP concentration, and Ymax refers to the fluorescence 
changes when all enzyme molecules are complexed with coenzyme. Curves fitting was performed 
using Origin® 9.1 Pro (OriginLab). 
 
2.7 Enzyme activity assays 
The decarboxylase activity was measured by a stopped spectrophotometric assay [29, 30]. Each 
variant enzyme (at appropriate concentration) was incubated under saturating PLP concentration 
(10 μM) and different L-Dopa concentrations in a final volume of 250 μL in 100 mM potassium 
phosphate buffer pH 7.4 for a time within which a linear product formation is observed. The 
reaction was then stopped by heating at 100 °C for 2 minutes. TNB (1 ml of a 4.3 mM solution) and 
toluene (1.5 ml) were added and the extraction of trinitrophenyl-derivative was carried out at 42 °C 
for 45 minutes with continuous shaking. The concentration of trinitrophenyl-derivative in the 
toluene layer was quantified using prepared calibration curve of absorbance at 340 nm as a function 
of trinitrophenyl-derivative concentration [31]. The kinetic parameters were determined by fitting 
the data obtained with the Michaelis-Menten equation using Origin® 8 Pro (OriginLab). 
 
2.8 Spectroscopic measurements 
All spectral measurements were acquired in 100 mM potassium phosphate, pH 7.4, at 25°C. CD 
measurements were recorded with a Jasco J-710 spectropolarimeter at a scan speed of 50 nm/min 
with a band width of 2 nm at a protein concentration of 1-5 μM and 10 M of exogenous PLP for 
the holoenzymes. Thermal denaturation was performed by monitoring the CD signal at 222 nm of 4 
μM enzyme on a 25-90°C linear temperature gradient, with a temperature slope of 1°C/min. 
Intrinsic fluorescence emission spectra were monitored using a FP-750 Jasco spectrofluorometer at 
a protein concentration of 1 μM setting at 5 nm excitation and emission bandwidths upon excitation 
at 280 nm.  
 
2.9 Dynamic Light Scattering (DLS) 
Aggregation study was performed on a Zetasizer Nano ZS instrument (Malvern) with a constant 90° 
scattering angle and a 633 nm wavelength laser. Protein samples were prepared at 4 μM 
concentration under physiological conditions (58 mM potassium phosphate, pH 7.4 at 37 °C). The 
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buffer was filtered immediately before the use. 
 
2.10 HPLC analysis of coenzyme modification and dopamine formation 
Catalytically inactive AADC variants were incubated at 10 M protein concentration with 2 mM L-
Dopa in 100 mM potassium phosphate buffer, pH 7.4 at 25°C. Concentration-time curves were 
followed by withdrawing aliquots at time intervals and quenching the reaction by adding 
trichloroacetic acid to a final concentration of 10% (v/v). Proteins were then precipitated in ice and 
removed by centrifugation. Supernatants were analyzed by HPLC as described [32] using a Gemini 
C18 column (150 x 4.6 mm, Phenomenex, CA, USA) and performed on a Jasco PU-2080 Plus 
HPLC system equipped with a UV-1570 detector set at 295 nm. Samples were eluted in 50 mM 
potassium phosphate, pH 2.35, at a flow rate of 1 mL/min. Standard curves of peak area as a 
function of coenzyme or cyclic adducts concentration were prepared with commercially available 
PLP and coenzyme adducts obtained by synthesis.  
 
2.11 NMR experiments 
Before NMR analysis, the HPLC-purified compounds were exchanged in water, lyophilized and re-
dissolved in D2O. All the NMR spectra were recorded at 298 K on a 600 MHz Bruker AVIII HD 
spectrometer equipped with a TCI cryogenic probe. For the acquisition we used a spectral width of 
20 ppm, an acquisition time of 1.36 s, 32000 data points and 128 or 256 scans. NMR data were 
processed with Topspin 3.2. PLP and PMP peak assignments were confirmed by comparing the 
chemical shifts of the 1D 1H-NMR spectra with those from reference spectra deposited in the 
Biological Magnetic Resonance Data Bank (BMRB). The 1H-NMR peak assignments to the Pictet-
Spengler adduct were verified by comparing the chemical shifts with previously reported 
resonances [33] and supported by 2D correlation NMR experiment (TOCSY). 
 
2.12 Limited proteolysis in presence of the substrate analogue DME 
Protection studies against tryptic proteolysis were performed as described [32]. WT AADC and 
variants were incubated with the substrate analogue DME at concentration of 2 mM for 30 seconds, 
10 minutes and 30 minutes and then digested with trypsin for 10 minutes at the 1:50 (w/w) ratio. 
Proteolysis was stopped with the addition of trypsin inhibitor at the 1:10 (w/w) ratio and the 
reaction samples were then analyzed on a 10% (w/w) SDS-PAGE gel. 
 
2.13 Bioinformatics analyses 
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Human AADC sequence was aligned with 75 homologues sequences retrieved form Uniref-90 
database by the homolog search algorithm PSI-BLAST and aligned using Multiple Sequence 
Alignment software CLUSTALW on ConSurf server (http://consurf.tau.ac.il). A conservation score 
(9= highly conserved, 1= highly variable) was attributed to each residue. Structural analysis and in 
silico mutagenesis of the pig DDC (PDB: 1JS6 ; ~90% sequence identity with the human 
homologous) was carried out using Pymol 2.0 (The PyMOL Molecular Graphics System, Version 
2.0 Schrödinger, LLC.). BindProfX was used to predict changes in binding affinity upon mutations 
in the form of G (change in free energy of binding) values. The algorithm combines the FoldX 
physics-based potential with the conservation scores from pairs of protein-protein interaction 
surfaces sequence profiles. Interface residues and solvent accessible area (ASA) have been 
determined starting from the available crystal structure of pig DDC (PDB: 1JS6) by means of the 






3.1 Solubility and purification yields of the new AADC variants 
The 13 new AADC variants were examined for their presence in the soluble fraction. Soluble 
V60A, H70Y, F77L, G96R, A110E, F251S, L353P and R453C levels are similar with respect to the 
WT (more than 70%), while P210L, L222P, F237S, W267R and E283A are poorly expressed in the 
soluble fraction (10-30%) (Fig 2). The addition of PLP did not significantly improve expression of 
either the WT or the variants. A low expression level might be related to a solubility alteration at 
least in E. coli system, suggesting folding defects for low expressed variants. 
The insoluble fractions of the poorly expressed variants show that the amount of protein recovered 
in the pellet is slightly higher as compared to that of the WT (Fig S1). However, considering the 
high soluble/insoluble ratio of WT AADC expressed in E. coli system, even subtle differences in 
insoluble fractions might be indicative of high differences in protein solubility. 
Considering the protein yields after purification, some variants exhibit nearly good to good yields 
(30-85% with respect to the WT), including A110E, L353P, R453C, F251S, F77L and G96R. 
Others display low (5-10% for V60A and H70Y) and very low (less than 2% for E283A, P210L and 
W267R) yields. Unfortunately, it was not possible to purify L222P and F237S which were 
recovered in extremely low amounts (0.3%) preventing us to carry out a complete biochemical 
characterization. 
 
3.2 Aggregation of apoP210L and apoE283A 
Given the great variability in both solubility level and purification yield of the analyzed variants 
(already reported in sporadic cases for other characterized AADC variants [25, 35-37]), DLS 
analyses were carried out in order to evaluate the aggregation propensity of the purified enzymes 
under physiological conditions (58 mM potassium phosphate buffer, pH 7.4 at 37°C). DLS 
measurements of the holo and apo forms of the majority of AADC variants and of WT (Fig. 3A) do 
not show signs of aggregation suggesting that the enzyme is not prone to aggregate under these 
experimental conditions. Instead, apoP210L and apoE283A, even if at different extent, tend to 
aggregate as demonstrated by both the increase in kcps and the disappearance of the dimeric species 
(Fig. 3B and 3C). While dimeric apoE283A disappears in about 300 min, apoP210L aggregation 
process is much slower. This led us to conclude that some AADC variants in their apo form are 
prone to undergo an aggregation process. 
 
3.3 Secondary structure and thermal stability of the new AADC variants 
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The structural integrity of all variants in terms of secondary structure has been evaluated by 
measuring the far-UV CD spectra of all purified variants in the 190-260 nm region. The signals are 
superimposable to that of the WT indicating that the substitutions do not alter the secondary 
structure of the protein (data not shown). In order to determine the intrinsic stability, we measured 
the Tm's of holo and apo forms of all variants (Table 2) by following the loss of the dichroic signal 
at 222 nm under physiological conditions (58 mM potassium phosphate buffer, pH 7.4).  
As for the holo proteins, the value of Tm for F251S, W267R, L353P and R453C is almost identical 
to that of the WT. Instead, the Tm value (Tm(variant)-Tm(WT)) is consistently lower for V60A, A110E 
and E283A followed by F77L, G96R, H70Y and, to a lesser extent, P210L. 
The apo species of V60A, G96R and E283A evidence a marked decrease in Tm with respect of the 
WT, followed by L353P, P210L, F77L and A110E, while the others exhibit Tm of  2°C. 
It is interesting to note that the Tm(holo-apo) for the WT is of about 5 °C. This value, indicative of the 
different thermal stability of the holo and the apo form, is maintained (or even increased) for all 
variants but V60A, H70Y, F77L, A110E, and R453C. 
 
3.4 Aromatic amino acids dichroic and fluorescence signals and coenzyme dichroic 
microenvironment features of the new AADC variants 
We then measured signals, collected by near UV-CD and intrinsic fluorescence, related to aromatic 
amino acids environment to monitor possible folding alterations in AADC variants. The near UV-
CD at 280 nm provides insight into asymmetric aromatic amino acid residues, mainly tryptophan(s), 
located in an appropriate position, and is linked to a proper protein tertiary structure arrangement. 
While the holo forms of G96R, P210L, F251S, and E283A have a 280 nm CD signal very similar to 
that of the WT, the other variants exhibit decreases in the intensity of the 280 nm band, although at 
different extent, particularly relevant in V60A, F77L and A110E (Fig. 4A and 4B). Since the apo 
form has a spatial arrangement different from the holo one [27], it is useful to compare the 280 nm 
CD signals of the apo variants in order to better understand how substitutions exert their effects on 
the entire protein structure or if the modifications are confined to the PLP binding region. An 
analysis of the CD near UV bands of the apo forms (insets of Fig. 4A and 4B) reveals that they are 
almost superimposable to that of the WT, unless a subtle decrease of the 280 nm band in G96R, 
F251S and E283A and a more evident one in V60A and R453C.  
Interestingly, the signals in the near UV region of the holo forms of V60A, F77L, and A110E are 
not so much different from the corresponding ones in the apo species. 
The intrinsic fluorescence signal is measured to provide insight into the correct folding features of 
the enzyme. Following excitation at 280 nm, the fluorescence spectrum of holo WT is characterized 
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by an emission spectrum with a maximum at 332 nm indicative of the buried environment of the 
aromatic amino acid residues (Fig. S2). Those variants displaying a decrease of the 280 nm CD 
band present in general an emission band higher than that of the WT, while the 332 nm 
fluorescence emission is similar to that of the WT for the other variants whose 280 nm CD band is 
identical or similar to that of the WT. Considering that consistent alterations of tertiary structure 
were found mainly in the holo forms, the deleterious effects of mutations are reasonably due to an 
impairment in the correct holo folding rather than to the achievement of the spatial structure of the 
apo form. 
It should be remembered that the apo WT emits at nearly the same wavelength as the holo but with 
higher intensity values given to different position of aromatic amino acids in this structure or to the 
energy transfer process from aromatic side chains fluorophores to the pyridine ring of the cofactor. 
This suggests that some variants remain in a sort of apo structure being somewhat prevented in the 
apo-to-holo transition or in the acquirement of a correct holo folding, as evidenced above. 
Altogether, these spectroscopic results witness slight alterations in global protein folding of the new 
variants. 
As for possible coenzyme microenvironment modifications, we measured the visible CD spectrum 
of all species. WT AADC presents two bands centered at 335 nm and 420 nm indicative of a 
tautomeric equilibrium between the enolimine and the ketoenamine forms of the internal aldimine 
that PLP forms with Lys-303. The spectra of the new variants display small differences with respect 
to the WT. In details, the spectra of H70Y, G96R, F251S and L353P are similar to that of the WT, 
while P210L and E283A exhibit a 420 nm band lower than the corresponding one of the WT. On 
the contrary, V60A, F77L, A110E and R453C show a predominance of the ketoenamine over the 
enolimine tautomer (Fig. 4A and 4B). Since this tautomeric equilibrium is unrelated with catalytic 
efficiency (see below), these results only reveal subtle PLP microenvironment modifications 
influencing the tautomeric equilibrium of the internal aldimine. 
 
3.5 Kinetic parameters and apparent PLP equilibrium dissociation constants, KD PLP, of new AADC 
variants 
The purified variants were functionally characterized by measuring their kinetic parameters. It 
could be observed (Table 3) that the catalytic efficiencies of P210L, F251S and E283A are not so 
much affected being 52%, 31% and 31%, respectively, compared to that of the WT. These values 
are due to a small decrease in kcat and nearly equal Km values for P210L, while in F251S and E283A 
the decrease of kcat is negligible with respect to that of the WT and Km is slightly increased. 
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W267R exhibits a catalytic efficiency value of 15% with respect to WT caused by a decrease in kcat 
of about 70% and an increase in Km of about 1.7-fold. 
The other variants (V60A, H70Y, F77L, G96R and R453C) are characterized by a marked decrease 
in catalytic efficiency. This drop is due to a concomitant strong decrease in kcat (mainly for V60A 
and H70Y) and increase in Km (mainly for G96R) or both (F77L and R453C). Notably, A110E and 
L353P are catalytically incompetent under the standard assay conditions.  
As for the coenzyme binding affinity, while the KD PLP is almost invariant for H70Y and P210L, it 
increases by 2 up to 5-fold in F77L, G96R, F251S, W267R and L353P and by 6 up to 10-fold in 
V60A, A110E, E283A and R453C. Thus, the cofactor in many variants is mispositioned and its 
contacts with the protein moiety are somewhat altered, as also witnessed by the visible CD signals. 
 
3.6 Some AADC variants convert PLP into cyclic Pictet-Spengler adduct in the presence of L-Dopa 
Among the variants, A110E and L353P seem to be severely impaired in catalysis since the kinetic 
parameters could not be measured under the standard assay conditions. Noteworthy, the addition of 
L-Dopa to both A110E and L353P leads to a decrease of the 420 nm absorbance band and an 
increase of the 335 nm band that slightly shifts to 329 nm with time. These absorbance bands are 
associated with the coenzyme bound at the active site. The spectral modifications are indicative of a 
reaction determining the conversion of the external aldimine between PLP and L-Dopa into an 
intermediate absorbing at ~ 330 nm, already observed for other AADC variants [35, 38] located in 
proximity of the active site and attributed to the Pictet-Spengler adduct [33]. The process is faster in 
A110E and slower in L353P (Fig. 5A and 5B). A reaction mixture containing 10 M A110E or 10 
M L353P with 2 mM L-dopa has been treated and subjected to HPLC analysis, as reported in 
Materials and Methods section. As shown in Fig. 5C and 5D, in both cases the PLP content 
decreases with an initial rate similar to that of the increase of the Pictet-Spengler cyclic adduct [32, 
33]. Table 4 shows the initial velocities, measured as slopes in the linear part of each curve (PLP 
decrease and Pictet-Spengler increase) for the two variants in comparison with free PLP under the 
same experimental conditions. It should be noted that a small amount of dopamine is also produced 
by both variants (Table 4). Given the fact that WT forms dopamine in the presence of saturating L-
Dopa (2 mM) with an initial velocity of 7.6 nanomol/sec/nanomol of enzyme (Table 3), it follows 
that the initial velocity of A110E is approximately 7.6•104 times and that of L353P of 6.8•103 times 
slower than that of the WT value under the same experimental conditions. It should be noted that, in 
the case of L353P, a small aliquot of pyridoxamine 5'-phosphate (PMP) is formed, due to the ability 
of AADC to catalyze multiple side reactions in addition to the main decarboxylation one [33].  
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While free PLP incubated with L-Dopa forms the cyclic adduct with an initial rate faster than in the 
two variants (Table 4), WT AADC does not form it since the protein moiety prevents unwanted 
reactions of its highly reactive coenzyme. This suggests that in both A110E and L353P the altered 
enzyme active site structure renders PLP rather free. The identification of the Pictet-Spengler 
adduct between L-Dopa and PLP was confirmed by NMR analyses [33] (Fig. S3). In order to check 
if the active site of the two catalytic variants is somewhat open or not capable of attaining the 
correct closed and catalytically competent conformation, we added to WT, A110E and L353P the 
substrate analog DME that binds to PLP but is unable to undergo decarboxylation. At the indicated 
times (Fig. 6), we subjected the enzyme-analog complex to limited proteolysis to monitor the extent 
of protection. It has been already demonstrated that [33] a protection from proteolysis is indicative 
of active site correct closure and productive catalysis. While WT does protect from proteolysis, 
both A110E and L353P do not protect, suggesting that some structural elements of the active site 
are altered and the closed catalytically competent conformation could not be attained.  
 
3.7 Bioinformatic analyses 
In order to verify the conservation level of the newly identified residues of AADC undergoing 
pathogenic substitution, the AADC amino acid sequence was aligned with those of 75 homologous 
proteins by the ConSurf web server. About 60% of the modified residues are highly conserved (His-
70, Phe-77, Ala-110, Leu-222, Phe-251, Trp-267, Glu-283 and Leu-353). Phe-237 is quite 
conserved and substituted only by apolar residues or amino acids endowed by a π-system. The 
others have a low conservation score, although the chemical nature of the residues (polar or apolar) 
is maintained for Val-60, Gly-96 and Pro-210, while Arg-453 resulted more prone to be substituted 
by several amino acids in homologous enzymes (Table S2). 
A bioinformatic analysis examining the arrangement of each residue undergoing substitution was 
then carried out to understand the in-silico impact of each substitution on protein structure and/or 
binding networks (Fig. 7A). 
Each monomer of AADC is composed of three domains: the N-terminal domain (residues 1-85) 
which comprises the structural element loop1 (residues 66-84), the large domain (residues 86-360), 
which in turn includes loop2 (residues 100-110), the PLP-Lys-303 loop (residues 300-310) and 
loop3 (residues 323-357, containing the flexible catalytic loop 328-339), and, finally, the C-
terminal domain (residues 361-480) [26, 27]. In the holo dimer the two monomers are strictly 
intertwined leading to a large interlocked interface and, as for the active site, the flexible catalytic 
loop together with loop1 of each subunit directly interacts with elements of the loops2 and 3 of the 
neighbouring one [27]. As for the role played by these key loops: loop1 is located in proximity to 
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the active site and is involved in the apo-to-holo conformational change of AADC [27], loop2 hosts 
residues near the active site, possibly interacting with the substrate moiety [25, 26], and loop3 is 
functionally essential for catalysis [26, 27, 31, 39]. 
Starting from the N-terminal stretch, Val-60 contributes to the monomer-monomer interface and its 
side chain engages the helix 85-99, that connects loop1 to loop2, of the neighbouring subunit by 
several hydrophobic contacts (Fig 7B). V60A modification reduces the inter-chain hydrophobic 
contacts within the two N-terminal regions of the AADC dimer. Moreover, the mispositioning of 
the helix 52-67, due to the substitution of Val-60 with Ala, affects the conformation of loop1. His-
70 and Phe-77 belong to loop1. In particular, His-70 side chain interacts with Tyr-20 by an H-bond 
linkage, while Phe-77 is involved mainly in a base-stacking interaction with the Phe-448 side chain 
(Fig 7C). Together His-70 and Phe-77 represent two anchoring points of loop1 and, of course, of 
the N-terminal and to the C-terminal domain influencing loop1 correct positioning.  
Gly-96 belongs to helix 85-99 at the end of loop1 and just before the beginning of loop2 (Fig 7B). 
Its backbone oxygen interacts with the Asn-308 side chain of the adjacent monomer in proximity of 
the active site. The G96R substitution could generate a consistent steric hindrance between the two 
antiparallel helices 85-99 probably perturbing the dimer assembly and the active site.  
Ala-110 is the last residue of loop2, belongs to the monomers interface and is placed into an apolar 
cavity (Fig 7D) at the beginning of the large domain. Its substitution with glutamate generates local 
steric hindrance between the two subunits and seems to exert some effects on the position of 
residues present at the active site (i. e. Phe-103 and Ile-101, that face PLP, and are part of loop2). 
This is corroborated by results obtained in the biochemical characterization and the molecular 
dynamics simulation of the recombinant A110Q protein [25].  
Pro-210, Leu-222, Phe-237 and Trp-267 belong to a β-barrel-helices system of the large domain 
that surrounds the active site. Such complex architecture is highly conserved in the large domain of 
PLP-dependent enzymes. In details, Pro-210 is placed on a flexible surface stretch (aa 209-218) 
joining a β-strand to a surface α-helix (Fig 7E). The P210L substitution exposes a hydrophobic 
residue on the protein surface probably inducing local structural rearrangement. Leu-222 belongs to 
the α-helix 218-232 and lies into a hydrophobic cleft (Fig 7E). The exchange to Pro could alter, or 
even interrupt, the α-helix folding causing a dramatic structural effect. Phe-237 and Trp-267 lie on 
two adjacent β-sheet elements and are involved in several hydrophobic contacts contributing to the 
folding features of the β-barrel (Fig 7F). It can be expected that the drastic changes of polarity and 
dimension of the residues introduced by the F237S or W267R substitutions could affect the proper 
folding of the β-strand/helices packaging. 
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Phe-251 lies on the loop 243-252 in proximity of the protein surface and takes place to a 
hydrophobic network involving residues of the large and C-terminal domains (Fig 7G). The 
substitution F251S does not generate significant steric hindrance but it is expected to abolish most 
of the hydrophobic contacts. 
Glu283 is exposed on the protein surface and contacts by a salt bridge the Arg379 side chain (Fig 
7H). This interaction represents the only connection between the helix 283-294 and the helix 372-
395 and, on the basis of the local microenvironment, might prevent the exposure of hydrophobic 
residues to the solvent. The E283A substitution abolishes such interaction and therefore generates a 
local conformational change by altering the relative position of surface secondary structure 
elements. 
Leu-353 belongs to loop3 of the large domain, and, in particular, is placed at the dimer interface, 
near the active site, at a proper distance to interact by hydrophobic contact with two residues: Phe-
103, a residue essential for the active site conformation [26] and Arg-347, a key catalytic residue 
[25, 31] (Fig 7D). This network is established in a region critical for catalysis and the substitution 
of Leu with Pro might determine deep effects on the active site architecture.  
Lastly, Arg-453, even if it belongs to the C-terminal domain, provides an additional junction 
between the C-terminal domain and the loop1, in fact the arginine side chain interacts with the Ser-
84 backbone oxygen through an H-bond (Fig 7C) and would favour loop1 correct conformation. 
Moreover, Arg-453 side chain is in proper position to interact with Met-1 backbone oxygen of the 
neighbouring subunit by a H-bond contributing to the monomer-monomer interaction.  
Considering that a significant number of the new mutations are localized at the dimer interface 
(V60A, G96R, A110E, L353P and R453C), we predicted the values of G of the monomer-
monomer interaction of WT AADC and of all interface variants using BindProfX (Table S3). 
Results indicate that, even if at different extent, all the interface mutations significantly destabilize 
the AADC dimer interface. 
 
4. Discussion 
In an effort to understand the molecular bases of AADC deficiency, our biochemical approach is 
aimed to unravel the structure-function relationships of the so-far identified variants in order to 
elucidate the enzymatic phenotypes. The present study is focused on 13 new pathogenic variants of 
AADC reported in literature from 2014 to 2019 in homozygosis and hemizygosis. At a first glance, 
it can be observed that these new amino acid substitutions are spread on the entire protein and not 
only in the central belt as the previously characterized mutations [25]. Until now, the previously 
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studied enzymatic phenotypes resulted in impaired apo-to-holo transition and catalysis [25, 31, 35, 
40].  
Following the investigations previously published [25], the loop1 variants H70Y and F77L 
resemble, in terms of catalytic efficiency and of structural conformation, the already studied ones 
affecting loop1 [25]. They are characterized by a drop in kcat and in catalytic efficiency. Less 
evident are the effects regarding KD(PLP). This behaviour is reasonably due to a stabilizing function 
of this region [25], whose alteration causes perturbation of both protein conformation and active site 
architecture. Moreover, the Tm's values with respect to the WT of both holo and apo proteins are 
notable and the holo-to-apo Tm's difference is diminished with respect to the WT, evidencing that 
substitutions in loop1 are characterized by a lesser variation in terms of degrees, arguing that these 
enzymatic species resemble apo rather than holo structures, as also shown by their spectroscopic 
signals. Interestingly, the clinical phenotypes of patients carrying these mutations are severe [10, 
13]. Overall, these new data support the fact that loop1 is crucial for apo-holo transition as 
suggested by [25].  
In addition to this, the remaining newly characterized variants allowed us to widen the spectrum of 
enzymatic phenotypes related to AADC deficiency. In particular, an interesting cluster of variants is 
represented by those belonging to the large domain (P210L, L222P, F237S, F251S, W267R and 
E283A). The bioinformatic analysis reveals that these residues are located either on the surface 
(P210L, F251S and E283A) or in hydrophobic environments (L222P, F237S and W267R). Except 
for F251S (see below), all of them are characterized by a low (or null) recovery in the soluble 
fraction. 
Since their apo near UV CD signals are similar to that of the apo WT and their holo near UV CD as 
well as intrinsic fluorescence spectra are not so much affected, it follows that these purified proteins 
do not present deep changes in their global structure. This can be correlated to the good catalytic 
efficiency as well as the quite high PLP affinity, unless for E283A, displayed by these variants. 
Thus, another mechanism for the pathogenicity for this class of variants should be considered in 
addition to the already proposed ones [25]. Indeed, the DLS analysis shows that apoE283A and 
apoP210L have a tendency to aggregate, while neither WT nor any of the other characterized 
variants has. Even if the time course of disappearance of the dimeric apoE283A and apoP210L is 
slow under our experimental conditions, it might represent a signal of a trend for these proteins to 
undergo an aggregation process in their apo form that in part explains the reason why the 
expression of these variants is so low. Only a small fraction is thus able to reach a competent state 
binding the coenzyme and performing catalysis, while the great part undergoes aggregation in the 
apo form. Notably, in the highly crowded cellular microenvironment the aggregation process might 
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be reinforced and facilitated, even if we have no information regarding relative rates of aggregation 
with respect to apo-to-holo transition. Interestingly, these two variants present a large effect of Tm 
of the holo and apo form with respect to holo and apo WT, suggesting that their structure is more 
labile. Consistently, the very low Tm value of apoE283A may be correlated with the aggregation 
propensity of this variant. The bioinformatic analyses support the possible protein misfolding effect 
caused by these variants. The affected soluble expression level of the other large domain variants 
suggests possible folding defects, whose process should be studied in a more appropriate cell 
model, as performed previously [40]. The low expression is also in line with what we have 
observed for R160W variant [37]. The reported clinical phenotypes of patients carrying these 
mutations are from mild to severe. Patients with F237S substitution have rather mild manifestations 
compared to others [12], reaching adulthood and for one of them a successful pregnancy has been 
reported [41]. The other clinical phenotypes are from intermediate to severe [13, 42], suggesting 
that alterations in the large domain could give rise to a wide spectrum of disease outputs. 
Phe-251 is an exception for this cluster of residues in the large domain since its substitution to Ser 
gives rise to a protein variant which behaves in a similar way to the already characterized S250F 
variant [40]. The bioinformatic analysis of F251S shows the modest effect exerted that is in line 
with the results obtained and with the mildness of the clinical phenotype of the patient [14]. This 
variant is only slightly affected by the substitution in catalytic parameters, in PLP affinity and in the 
spectroscopic signals.  
Considering the remaining new variants (V60A, G96R, A110E, L353P and R453C), their common 
feature is the belonging to the large interface of AADC. This interface comprises 144 residues of 
the total 480 amino acids of each monomer and covers the 27.3% of the total solvent-accessible 
area (ASA) of each subunit. In comparison, the dimer interface of the prototype of Fold-Type I 
PLP-enzymes, aspartate aminotransferase, covers only 19.8% of the total ASA. The AADC 
interface goes through the contact surface of the two subunits crossing different regions from the N-
terminal to the large domain and to, finally, the C-terminal. Taken together, interface variants could 
be distinguished in those showing modest effects on catalysis (V60A, G96R and R453C) or large 
catalytic drops (A110E and L353P). This is expected since they affect different protein regions and 
may exert long-range effects acting at the strictly tight monomer-monomer interface of AADC. 
Since the active sites are at the interface, a defect in this wide part of the protein might affect 
catalysis and/or coenzyme binding. 
The interface variants V60A, G96R and R453C are characterized by a low catalytic efficiency due 
to low kcat for V60A and R453C and high Km for G96R. This could be also mirrored by the fact that 
the affinity for the coenzyme is compromised in V60A and R453C, as well as the environment of 
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aromatic amino acids, and decreased in G96R. Their Tm variations are similar to those recorded 
for loop1 variants, however the measured G values show that the interaction networks between 
monomers is here affected. The bioinformatic analyses show that Val-60 and Gly-96 maintain the 
protein interface and are thus involved in dimer assembly, while the effect of Arg-453 on interface 
affects N-terminal and loop1 proper positioning. Notably, V60A and G96R display the lowest 
values of Tm for their apo structures, supporting the stabilizing role for this interface region. The 
effects for R453C are less pronounced and this might in part be related to the observation that 
patients with R453C substitution have a milder clinical phenotype than the others of this group [43]. 
A110E and L353P are interface variants with strong catalytic impairments. Both A110E and L353P 
exhibit a change in the aromatic amino acid environment even if at a different extent. Moreover, the 
lack of catalytic activity, the irreversible trapping of the coenzyme into a cyclic inactive form and 
the incapability of these variants to protect from proteolysis in the presence of the substrate analog 
DME, witness a direct effect of the substituted residues in the active site. This effect is expected 
since both residues are located in proximity to critical amino acids at the active site such as Ile-101, 
Phe-103 and Arg-347. The critical role of Arg-347 has already been discussed [31]. Other AADC 
variants near the active site have been previously described and were able to perform Pictet-
Spengler condensation reaction [35] even if at a slower rate. The G value for A110E and L353P 
is positive and suggests that a proper active site closure depends on a productive dimeric assembly. 
This alteration is also witnessed by changes in Tm values with respect to the WT of both holo and 
apo A110E (whose Tm(holo-to-apo) in terms of degrees is of only 1°C) and apo L353P. It derives that 
AADC residues affecting catalysis are positioned not only at the active site but also at the dimer 
interface affecting elements of the active site directly (such as Leu-353) or by long-range 
interactions (such as Ala-110). It is not strange that patients bearing these mutations are severely 
affected [13, 44]. 
Altogether, the combination of bioinformatic analyses with biochemical data has been useful in 
defining the behaviour of enzymatic variants and deepens the knowledge on enzymatic phenotypes. 
We have here characterized a new enzymatic phenotype leading to aggregation of AADC variants 
that open the way on investigations regarding the variants with the hallmark of being low 
expressed. Furthermore, we have encountered new types of variants located at the protein interface 
able to play short-range (L353P) and long-range (V60A, G96R, A110E and R453C) effects at the 
active site, highlighting the importance of the large interface of AADC in protein proper 
functioning. 
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The ultimate aim of our approach is to correlate the position of each mutation occurring in a defined 
protein region to the severity of the enzymatic phenotype in order to contribute in the understanding 
of the clinical phenotype. 
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5. Legends to Figures 
 
Fig. 1-New and already identified amino acid substitutions in AADC variants. Ribbons 
representation of the holo AADC (pdb ID 1JS6). The two monomers are white and light orange, 
respectively, and PLP molecules are represented as green sticks. Mutation sites of previously 
characterized variants and new variants are presented as orange and yellow sticks, respectively. 
Image was rendered by PyMol software (Schrödinger). 
 
Fig. 2- Soluble fractions of WT and variants AADC. Western blot analysis is performed with 10 
g of total protein content from soluble lysates of E. coli loaded on 12% acrylamide gel. Each 
bacteria culture has been grown in absence (-) and presence (+) of exogenous PLP. Determination 
of the expression levels of each variant was estimated using ImageJ software (Fiji) and is reported 
in the text as percentage with respect to the WT. 
 
Fig. 3-DLS analyses of apo WT, apo P210L and apo E283A as a function of time. 
4 M apo WT (A), apo P210L (B) and apo E283A (C) are incubated in 58 mM potassium 
phosphate buffer pH 7.4 at 37°C. Grey open symbols indicate the size of the dimer, solid squares 
indicate the mean count rate. 
 
Fig. 4-Near UV and visible CD spectra of WT AADC and variants in their holo and apo 
forms. 
The spectra are recorded at 5 M protein concentration, in 100mM potassium-phosphate buffer, pH 
7.4. Spectra of the holo forms are recorded in the presence of 10 M PLP. (A) The holo forms of: 
WT, F251S, E283A, G96R. (B) The holo forms of:  WT, P210L, L353P, R453C, H70Y, A110E, 
V60A and F77L. Spectra of the corresponding apo forms are reported in the insets. 
 
Fig. 5-Absorbance spectra of A110E and L353P in the presence of L-Dopa. To a solution of 10 
M A110E (A) and L353P (B), L-Dopa has been added and spectra are recorded with time in 100 
mM potassium phosphate buffer, pH 7.4 at 25°C. Dotted line: variant without L-Dopa. The arrows 
indicate the increase at 329 nm and the concomitant decrease at 420 nm with time following 
addition of 2 mM L-Dopa. Insets: increase of the 329 nm and decrease of the 420 nm signals as a 
function of time. HPLC analyses results of the reaction mixture of 10 M A110E (C) and L353P 
(D) in the presence of 2 mM L-Dopa in 100 mM potassium phosphate buffer, pH 7.4 at 25°C. PLP 
( ), Pictet-Spengler PLP-L-Dopa ( ), dopamine ( ) and PMP ( ). 
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Fig. 6-Limited tryptic proteolysis of WT (A), A110E (B) and L353P (C) in the presence of 
DME. WT, A110E and L353P are incubated at a concentration of 10 M protein with 2 mM DME 
for various times and then digested with trypsin for 10 minutes at the trypsin/enzyme ratio 1:50 
(w:w). t0 is the control in the absence of trypsin. 
 
Fig. 7-In silico inspection of the mutation sites. Ribbons representation of the holo AADC (pdb 
ID 1JS6). The two monomers are white and light orange, respectively, loop1 (aa 66-84) is magenta 
and PLP molecules are represented as green sticks. In each panel: (i) the mutation sites are indicated 
and represented as yellow sticks; (ii) specific interacting residues are in cyan; (iii) clusters of 
hydrophobic residues are represented as orange sticks. *residues belonging to the neighboring 




Table 1. New reported AADC homozygous or hemizygous variants from 2014 to 2019. 
new variant reference Note 
V60A Hwu et al., 2017 [13] in hemizygosis, the other allele produces a 
protein that ends prematurely at 248 amino 
acids, with no formation of the active site 
H70Y Manegold et al., 2009 [10];  
Gucuyener et al., 2014 [45] 
Montioli et al., 2014 [25] 
homozygous, reported incorrectly as H70T 
F77L www.bioku.org/pnd/home.asp 
 
homozygous, on line submission in 
database in 2012 
G96R Hwu et al., 2017 [16] in hemizygosis, the other allele produces a 
protein that ends prematurely at 248 amino 
acids, with no formation of the active site 
A110E Ide et al., 2010 [44]; 
Wassenberg et al., 2010 [46]; 
Montioli et al., 2014 [25] 
homozygous, reported incorrectly as 
A110Q 
P210L Helman et al., 2014 [42] in hemizygosis, the other allele has a 
mutation leading to a premature stop codon 
L222P Helman et al., 2014 [42] Homozygous 
F237S Leuzzi et al., 2015 [12] in hemizygosis, the other allele has a 
mutation leading to a premature stop codon 
F251S Chien et al., 2016 [14] in hemizygosis, the other allele produces a 
protein that ends prematurely at 248 amino 
acids, with no formation of the active site 
W267R R. Pons, personal 
communication 
homozygous, R. Pons, personal 
communication 
E283A Hwu et al., 2017 [13] in hemizygosis, the other allele produces a 
protein that ends prematurely at 248 amino 
acids, with no formation of the active site 
L353P Hwu et al., 2017 [13] in hemizygosis, the other allele produces a 
protein that ends prematurely at 248 amino 
acids, with no formation of the active site 




Table 2: Melting Temperatures of WT AADC and variants. Melting temperature values 
obtained by following the CD signal at 222 nm and varying the temperature linearly from 25 to 
90°C with a slope of 1.5 °C/min.    
 
Tm (°C) 
Enzyme holo apo 
WT 69.42 ± 0.02 64.84 ± 0.03 
V60A  62.13 ± 0.02 59.30 ± 0.03 
H70Y 65.95 ± 0.04 63.28 ± 0.05 
F77L 63.58 ± 0.03 61.70 ± 0.03 
G96R 65.64 ± 0.05 58.46 ± 0.04 
A110E 63.20 ± 0.05 62.04 ± 0.04 
P210L 66.10 ± 0.10 60.91 ± 0.05 
L222P n.d n.d 
F237S n.d n.d 
F251S 70.49 ± 0.04 63.37 ± 0.06 
W267R 70.30 ± 0.10 63.60 ± 0.03 
E283A 62.89 ± 0.02 58.66 ± 0.07 
L353P  68.10 ± 0.07 60.82 ± 0.03 






Table 3. Steady-state kinetic parameters and apparent equilibrium dissociation constant, Kd, 
for PLP of the new AADC variants. 
 
Enzyme kcat (s
-1) Km (mM) kcat/Km 
(s-1 mM-1) 
KD PLP (nM) 
WT 7.6 ± 0.1 0.11 ± 0.01 69.1 ± 10 43 ± 12 
V60A 0.93 ± 0.02 0.16 ± 0.01 5.8 ± 0.4 252 ± 35 
H70Y 0.58 ± 0.09 0.26 ± 0.04 2.2 ± 0.5 70 ± 18 
F77L 0.35 ± 0.07 0.51 ± 0.05 0.7 ± 0.1 222 ± 38 
G96R 5.7 ± 0.4 3.5 ± 0.4 1.6 ± 0.2 132 ± 14 
A110E n.d. n.d. n.d. 321 ± 26 
P210L 4.4 ± 0.2  0.12 ± 0.02 37 ± 6 47 ± 7 
L222P n.p. n.p. n.p. n.p. 
F237S n.p. n.p. n.p. n.p. 
F251S 5.7 ± 0.2 0.26 ± 0.02 22.0 ± 0.2 88 ± 16 
W267R 2.11 ± 0.04 0.19 ± 0.01 11.1 ± 0.6 120 ± 10 
E283A 6.4 ± 0.2 0.29 ± 0.05 22.0 ± 0.2 330 ± 30 
L353P n.d. n.d. n.d. 199 ± 34 
R453C 0.67 ± 0.07 0.40 ± 0.06 1.7 ± 0.3 468 ± 36 
n.d., not detectable under standard assay conditions; n.p., not purified 
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Table 4. Initial velocities of dopamine formation, PLP decrease, Pictet-Spengler and PMP 
increase following reaction of 10 M A110E or L353P or 20 M PLP with 2 mM L-Dopa  
initial velocity (v0) 
(nmol/min/nmol) 
A110E L353P free PLP 
v0 dopamine 0.006  0.001 0.067  0.001 -- 
v0 PLP decrease 0.040  0.004 0.006  0.002 0.12  0.01 
v0 Pictet-Spengler 0.042  0.006 0.005  0.003 0.10  0.04 
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